Pexidartinib

Pexidartinib is an orally available small molecule that acts as a potent inhibitor of the colony-stimulating factor 1 receptor (CSF1R). It represents a targeted therapy for certain proliferative disorders involving macrophages.

Drug Overview

• Generic Name: Pexidartinib
• US Brand Names: Turalio®
• Drug Class: Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitor, Kinase Inhibitor
• Route of Administration: Oral (Capsule)
• FDA Approval Status: Approved for oncological indications

What Is It and How Does It Work? (Mechanism of Action)

Pexidartinib is a kinase inhibitor that works primarily by blocking signaling pathways driven by the CSF1R. This mechanism is crucial for controlling the proliferation of specific immune cells implicated in certain localized tumors.

• Molecular Target: Pexidartinib selectively and potently inhibits the kinase activity of Colony-Stimulating Factor 1 Receptor (CSF1R). It also inhibits KIT (CD117) and FLT3, although its primary clinical relevance is through CSF1R.
• Cellular Impact: In Tenosynovial Giant Cell Tumor (TGCT), the tumor-initiating cells often produce excessive Colony-Stimulating Factor 1 (CSF1). This excess CSF1 attracts and stimulates the proliferation of CSF1R-expressing cells, primarily macrophages (histiocytes) and osteoclast-like giant cells, leading to tumor growth.
• Result (Anti-Proliferation/Apoptosis): By blocking the binding of CSF1 to its receptor (CSF1R), pexidartinib inhibits the signaling cascade that drives the proliferation, survival, and differentiation of these CSF1R-dependent cell populations. This disruption reduces the number of macrophages and giant cells within the tumor tissue, causing tumor shrinkage.
• Bone Affinity: This mechanism targets the highly proliferative synovial macrophages (histiocytes) and osteoclast-like cells found in the joint, which contribute to bone erosion in advanced TGCT.

FDA-Approved Clinical Indications

Pexidartinib is FDA-approved for a single, specific indication related to localized, but debilitating, tumor growth.

Oncological Uses

• Tenosynovial Giant Cell Tumor (TGCT): Indicated for adult patients with symptomatic Tenosynovial Giant Cell Tumor (also known as pigmented villonodular synovitis or PVNS) that is associated with severe morbidity or functional limitations and is not amenable to improvement with surgery.

Non-oncological Uses

• No current FDA-approved non-oncological indications were found.

Dosage and Administration Protocols

Pexidartinib is administered orally as a continuous treatment until disease progression or unacceptable toxicity. It is subject to a Risk Evaluation and Mitigation Strategy (REMS) program due to the risk of serious liver injury.

Dose Adjustments and Special Considerations

Clinical Efficacy and Research Results

Pexidartinib is the only systemic therapy approved for TGCT, based on its efficacy in significantly reducing tumor volume and improving functional outcomes.

• Overall Response Rate (ORR) (ENLIVEN Study): In the pivotal Phase 3 ENLIVEN trial, the ORR (defined as partial or complete response) was 39% in the pexidartinib group versus 0% in the placebo group.
• Median Time to Response: Responses were achieved relatively quickly, with a median time to response of 14.8 weeks.
• Durable Response: Responses were shown to be durable, with the median duration of response not yet reached.
• Functional Improvement (2020-2025 Context): Patient-reported outcomes demonstrated functional benefits. At 24 weeks, the mean change in the range of motion (ROM) was significantly improved in the pexidartinib arm compared to placebo. The response rate among patients with a complete tumor response was approximately 28.6%.

Safety Profile and Side Effects

Black Box Warning: Hepatotoxicity

Pexidartinib can cause serious and potentially fatal liver injury. The most severe adverse reactions include mixed-type liver injury, cholestatic liver injury, and hepatic failure, sometimes leading to liver transplant. The drug is available only through a Risk Evaluation and Mitigation Strategy (REMS) program.

Common Side Effects (>10%)

• Hepatic: Increased AST, increased ALT, increased alkaline phosphatase (ALP).
• Systemic: Fatigue, headache, dizziness, dysgeusia (altered taste).
• Gastrointestinal: Nausea, diarrhea.
• Hair/Skin: Hair color changes (hyperpigmentation/hypopigmentation).

Serious Adverse Events

4. Severe Hepatotoxicity: Cases of severe and fatal drug-induced liver injury have been reported. LFT monitoring is mandatory prior to initiation, every week for 8 weeks, then every 2 weeks for the next 4 months, and every 3 months thereafter.
5. Cholesterol and Lipid Elevation: Severe hypercholesterolemia and hypertriglyceridemia can occur.
6. Embryo-Fetal Toxicity: Pexidartinib can cause fetal harm when administered to a pregnant woman.
7. QT Prolongation: The drug has the potential to prolong the QT interval, which can lead to serious cardiac arrhythmias.

Connection to Stem Cell & Regenerative Medicine

Pexidartinib’s action on CSF1R is a direct intersection with regenerative medicine, as the CSF1/CSF1R axis is fundamental to macrophage biology and tissue homeostasis:

• Targeting Macrophage Progenitors: The drug works by blocking the proliferation and survival of cells (macrophages and osteoclast-like cells) that originate from hematopoietic stem cell progenitors and infiltrate tissues. Its mechanism directly controls the downstream effect of the local microenvironment on these lineage-specific progenitor cells.
• Potential in Bone/Joint Degeneration: By reducing the population of osteoclast-like giant cells within the joint, pexidartinib has a localized “regenerative” or protective effect on the surrounding joint tissues and bone, mitigating the severe joint destruction associated with advanced TGCT.
• Research Areas in CNS/Microglia: CSF1R signaling is crucial for the development and maintenance of microglia, the brain’s resident macrophages. Pexidartinib and other CSF1R inhibitors are being investigated in preclinical and clinical settings for neurological diseases driven by microglial over-activation, such as Alzheimer’s and Multiple Sclerosis.

Patient Management and Practical Recommendations

Pre-treatment

• Liver Function Tests (LFTs): Baseline AST, ALT, and total bilirubin must be obtained.
• Pregnancy Test: Women who can become pregnant must have a negative pregnancy test prior to starting therapy.
• Lipid Panel: Baseline cholesterol and triglyceride levels should be obtained.

Precautions During Treatment

• Mandatory LFT Monitoring: Liver function must be monitored every week for the first 8 weeks, every 2 weeks for the next 4 months, and every 3 months thereafter.
• Dietary Restriction: Capsules must be taken with a low-fat meal (11-14 grams of fat) to ensure consistent absorption.
• Cardiac Monitoring: Use with caution in patients with a history of heart rhythm problems or prolonged QT interval.

Do’s and Don’ts

• DO:
  • DO: Immediately report any signs of liver injury, such as yellowing of the skin or eyes (jaundice), dark urine, upper right stomach pain, or unusual fatigue.
  • DO: Keep all scheduled lab appointments for LFTs; this monitoring is mandatory and essential for safe treatment.
  • DO: Use effective non-hormonal contraception during treatment and for at least 1 month after the last dose if you or your partner can become pregnant.
• DON’T:
  • DON’T: Begin or continue Pexidartinib if you have moderate or severe hepatic impairment (Child-Pugh B or C).
  • DON’T: Skip doses or take extra doses. If a dose is missed, skip it and take the next dose at the regular time.
  • DON’T: Breastfeed during treatment and for 1 month after the last dose.

Legal Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status, concurrent therapies, and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding specific medical conditions and treatment plans.